The implementation of measles, mumps, and rubella (MMR) vaccination programs resulted in a major global reduction in morbidity and death from these infections. In the United States of America, the current recommended MMR immunization schedule consists of two vaccine doses, commonly provided at 12–15 months and 4–6 years, respectively. Given previous outbreaks in the United States, catch-up immunization with an additional dose of MMR vaccine may help with outbreak control and community protection. This phase III, observer-blind, randomized controlled study (NCT02058563) evaluated the immunogenicity and safety of the MMR-RIT vaccine (Priorix, GSK) to the MMR II vaccine (control; M-M-R II, Merck & Co Inc.) in 7-year-olds who had previously received one dose of MMR vaccination.
On day 42 after vaccination, researchers measured anti-measles, anti-mumps, and anti-rubella antibody geometric mean concentrations (GMCs; main endpoint) and zero response rates (SRRs). There were solicited, unsolicited, and significant adverse events (AEs) documented. The protocol-compliant cohort for immunogenicity contained 869 patients (MMR-RIT: 433; MMR II: 436).
After a dosage of MMR-RIT, they observed anti-measles, anti-mumps, and anti-rubella antibody GMCs of 1790.2 mIU/mL, 113.5 EU/mL, and 76.1 IU/mL, respectively, and SRRs of 98.8%, 98.4%, and 99.5%, respectively; non-inferiority to MMR II was demonstrated. Both vaccinations had equivalent reactogenicity profiles; the most frequently reported AEs were injection site redness and discomfort, as well as fever (MMR-RIT: 12.2%, 11.8%, and 3.0%; MMR II: 11.7%, 11.5%, and 5.2%, respectively). The MMR-RIT dosage elicited powerful immunological responses that were comparable to MMR II and were well tolerated.
Reference:www.tandfonline.com/doi/full/10.1080/21645515.2018.1489186
